A comprehensive view of AstraZeneca AB. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca expands Healthy Heart Africa program to 10 more countries in Africa starting in 2023; program intended to prevent, control hypertension, which accounted for 1 million deaths in Sub-Saharan Africa in 2019 according to World Heart Federation

AstraZeneca earns the Best Place to Work Certification across its operations in North Africa and Levant

AstraZeneca withdraws US COVID-19 vaccine application for Vaxzevria, shifts focus to antibody treatment Evusheld; Evusheld is approved in US to prevent COVID in immunocompromised people and in Europe as a preexposure prophylactic and as a treatment

India approves AstraZeneca’s Dapagliflozin for diabetes patients with chronic kidney disease; the drug significantly reduces risk of sustained estimated glomerular filtration rate, cardiovascular deaths, hospitalizations due to heart failure

AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022 December 10-13; eight approved and potential new medicines to be featured across more than 10 types of blood cancers and rare diseases

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count